Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 6,564,599 shares, a drop of 27.6% from the March 31st total of 9,069,811 shares. Approximately 13.1% of the company’s stock are sold short. Based on an average daily trading volume, of 788,190 shares, the days-to-cover ratio is currently 8.3 days.

Dianthus Therapeutics Trading Down 0.4%

NASDAQ:DNTH traded down $0.38 during mid-day trading on Friday, hitting $87.42. The stock had a trading volume of 487,242 shares, compared to its average volume of 561,756. Dianthus Therapeutics has a twelve month low of $16.64 and a twelve month high of $96.50. The company’s 50 day simple moving average is $78.79 and its 200 day simple moving average is $54.90.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. Sell-side analysts forecast that Dianthus Therapeutics will post -4.46 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target on the stock. Wolfe Research initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $98.00 price objective for the company. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Robert W. Baird lifted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and an average target price of $115.55.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total transaction of $738,844.16. Following the completion of the transaction, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,021 shares of company stock worth $26,564,008 in the last 90 days. 3.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. First Horizon Corp bought a new position in shares of Dianthus Therapeutics during the first quarter worth approximately $32,000. Virtus Investment Advisers LLC grew its holdings in Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after buying an additional 416 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the period. Royal Bank of Canada lifted its holdings in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.